HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lebrun, C M Articles by Prior, J C Search for Related Content PubMed PubMed Citation Articles by Lebrun, C M Articles by Prior, J C

Decreased maximal aerobic capacity with use of a triphasic oral contraceptive in highly active women: a randomised controlled trial

Fowler Kennedy Sport Medicine Clinic 3M Centre, University of Western Ontario, London, ON N6A 3K7, Canada

Correspondence to:
Correspondence to:
Dr Lebrun, Fowler Kennedy Sport Medicine Clinic 3M Centre, University of Western Ontario, London, ON, Canada N6A 3K7;
clebrun{at}uwo.ca

Background: Oral contraceptives are commonly used by women athletes. However, their effect on athletic performance is unclear.

Objectives: To examine the effects of a moderate dose, triphasic oral contraceptive on measures of athletic performance in highly trained women athletes.

Methods: This is a double blind, placebo controlled trial in 14 women with ovulatory menstrual cycles and maximal aerobic capacity (VO₂MAX) 50 ml/kg/min. Four measures of athletic performance were tested: VO₂MAX, anaerobic capacity (anaerobic speed test), aerobic endurance (time to fatigue at 90% of VO₂MAX), and isokinetic strength (Cybex II dynamometer). Height, weight, and six skinfold measurements were also recorded. All these observational tests were completed during both the follicular and mid-luteal phases of an ovulatory menstrual cycle. Cycle phases were confirmed by assaying plasma oestradiol and progesterone. Participants were subsequently randomly assigned to either a tricyclic oral contraceptive or placebo and retested in identical fashion (oral contraceptive phase).

Results: Absolute and relative changes in VO₂MAX from follicular to oral contraceptive phase decreased in the oral contraceptive group by 4.7%, whereas the placebo group showed a slight increase (+1.5%) over the same time period. Two of the women taking oral contraceptive had decreases of 4 and 9 ml/kg/min. In contrast, most women in the placebo group improved or maintained VO₂MAX. There was also a significant increase in the sum of skinfolds in women taking oral contraceptive compared with those taking placebo (p<0.01). There were no significant changes in other physiological variables (maximum ventilation, heart rate, respiratory exchange ratio, packed cell volume) or measures of performance (anaerobic speed test, aerobic endurance, isokinetic strength) as a function of oral contraceptive treatment.

Conclusions: The decrease in VO₂MAX that occurs when oral contraceptive is taken may influence elite sporting performance in some women. Further studies are required to determine the mechanisms of this change.

Keywords: athletic performance; oestradiol; menstrual cycle; oral contraceptive; progesterone

This article has been cited by other articles:

				Minerva BMJ, November 22, 2003; 327(7425): E258 - 258. [Full Text] [PDF]

				Minerva BMJ, August 16, 2003; 327(7411): 402 - 402. [Full Text] [PDF]